HLA-E*01:03&B2M&Peptide (VMAPRTLVL) Monomer, His & Avi, Human
HLA-E*01:03&B2M&Peptide (VMAPRTLVL) Monomer, His & Avi, Human

Immobilized HLA-E*01:03&B2M&Peptide (VMAPRTLVL) Monomer, His & Avi, Human, His Tag at 1 μg/ml(100 μl/well) on the plate. Dose response curve for Anti-B2M Antibody, mFc Tag with the EC50 of 12.3 ng/ml determined by ELISA.

HLA-E*01:03&B2M&Peptide (VMAPRTLVL) Monomer, His & Avi, Human

The purity of HLA-E*01:03&B2M&Peptide (VMAPRTLVL) Monomer, His & Avi, Human is greater than 95% as determined by SEC-HPLC.

HLA-E*01:03&B2M&Peptide (VMAPRTLVL) Monomer, His & Avi, Human

HLA-E*01:03&B2M&Peptide (VMAPRTLVL) Monomer, His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

HLA-E*01:03&B2M&Peptide (VMAPRTLVL) Monomer, His & Avi, Human

HLA-E is a nonclassical member of the major histocompatibility complex class I gene locus. HLA-E protein shares a high level of homology with MHC Ia classical proteins: it has similar tertiary structure, associates with β2-microglobulin, and is able to present peptides to cytotoxic lymphocytes. The main function of HLA-E under normal conditions is to present peptides derived from the leader sequences of classical HLA class I proteins, thus serving for monitoring of expression of these molecules performed by cytotoxic lymphocytes.
Z06645
¥63,425.00

Ask us a question
Product Introduction
Species Human
Protein Construction
HLA-E*01:03&B2M&Peptide (VMAPRTLVL) Monomer [ Gly22-Thr302(HLA-E*01:03), Ile21-Met119(B2M) and VMAPRTLVL peptide]
Accession # P13747(HLA-E*01:03)&P61769(B2M)&VMAPRTLVL		 His Avi
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA.Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 50.2 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 52-60 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.

Examples
  • HLA-E*01:03&B2M&Peptide (VMAPRTLVL) Monomer, His & Avi, Human
    • HLA-E*01:03&B2M&Peptide (VMAPRTLVL) Monomer, His & Avi, Human

    Immobilized HLA-E*01:03&B2M&Peptide (VMAPRTLVL) Monomer, His & Avi, Human, His Tag at 1 μg/ml(100 μl/well) on the plate. Dose response curve for Anti-B2M Antibody, mFc Tag with the EC50 of 12.3 ng/ml determined by ELISA.

  • HLA-E*01:03&B2M&Peptide (VMAPRTLVL) Monomer, His & Avi, Human
    • HLA-E*01:03&B2M&Peptide (VMAPRTLVL) Monomer, His & Avi, Human

    The purity of HLA-E*01:03&B2M&Peptide (VMAPRTLVL) Monomer, His & Avi, Human is greater than 95% as determined by SEC-HPLC.

  • HLA-E*01:03&B2M&Peptide (VMAPRTLVL) Monomer, His & Avi, Human
    • HLA-E*01:03&B2M&Peptide (VMAPRTLVL) Monomer, His & Avi, Human

    HLA-E*01:03&B2M&Peptide (VMAPRTLVL) Monomer, His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background HLA-E is a nonclassical member of the major histocompatibility complex class I gene locus. HLA-E protein shares a high level of homology with MHC Ia classical proteins: it has similar tertiary structure, associates with β2-microglobulin, and is able to present peptides to cytotoxic lymphocytes. The main function of HLA-E under normal conditions is to present peptides derived from the leader sequences of classical HLA class I proteins, thus serving for monitoring of expression of these molecules performed by cytotoxic lymphocytes.
Synonyms HLAE; sHLA-E; HLAE; MHC class I antigen E; MHC HLA-E alpha-1; MHC HLA-E alpha-2.1; MHC; QA1

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.